<DOC>
	<DOCNO>NCT00909506</DOCNO>
	<brief_summary>The investigator hypothesize adjuvant metformin use breast cancer patient overweight pre-diabetes mellitus ( DM ) may improve body condition include weight loss . In study , investigator aim test efficacy safety adjuvant metformin operable breast cancer patient overweight pre-DM .</brief_summary>
	<brief_title>Efficacy Safety Adjuvant Metformin Operable Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Operable Breast cancer patient BMI ≥ 23 100 ≤ FBS &lt; 126 From 6 month 2 year since breast cancer operation least 4 week since chemotherapy radiotherapy No drug use except Tamoxifen Normal OTPT &amp; Serum creatinine ( &lt; =ULN ) ECOG performance status 02 Karnofsky PS 60100 % Life expectancy &gt; 12 Absolute neutrophil count ≥ 1.5 x 10^9/L Platelets ≥ 100 x 10^9/L Pregnancy ( ) &amp; without plan pregnancy Sign write informed consent form Type I II DM concurrent use DM control agent Prior use Metformin Hypoglycemia ( FBS &lt; 70 clinical symptom ) Concurrent investigational commercial agent Other diet drug intervention weight loss Concurrent use steroid Abnormal liver and/or renal function Symptomatic congestive heart failure / Cardiac arrhythmia / Angina pectoris Ongoing active infection lactic acidosis Pregnancy ongoing breast feeding Anorexia , bulimia , nausea due disease longer 1 month Allergies allergic reaction attribute oral medication Inability swallow digest oral medication Physical psychiatric illness would limit compliance study protocol Participants clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>